Zacks Small Cap Research on MSN

FBLG: Phase 1/2 trial of CYWC628 underway

By David Bautz, PhD NASDAQ: FBLG Business Update Phase 1/2 Trial of CYWC628 Underway On June 3, 2026, FibroBiologics, Inc.
Seeking Alpha

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR BEMARITUZUMAB IN FIBROBLAST GROWTH FACTOR RECEPTOR 2b (FGFR2b) POSITIVE FIRST-LINE GASTRIC CANCER

At an Interim Analysis, Bemarituzumab Plus Chemotherapy Significantly Improved Overall Survival in People With FGFR2b Overexpression Compared to Chemotherapy Alone THOUSAND OAKS, Calif., June 30, 2025 ...

Exclusive: FibroBiologics doses first patients in diabetic foot ulcers clinical trial

FibroBiologics Inc. FBLG on Wednesday announced that it has enrolled and dosed the first patients in its Phase 1/2 clinical trial evaluating CYWC628 for the treatment of diabetic foot ulcers (DFUs).
ascopubs.org

First-in-human phase 1 dose escalation trial of OMTX705, a novel anti-fibroblast activation protein (FAP) antibody drug conjugate (ADC), in monotherapy and in combination with ...

Association of genomic alterations in circulating tumor DNA (ctDNA) with clinical response to telisotuzumab vedotin (Teliso-V) in 2L+ EGFR wildtype (EGFRwt) non-squamous non-small cell lung cancer ...
EurekAlert!

Cells usually viewed as menders may harm the heart

Jen Davis (left) and Bella Reichardt (right) conducting research in a lab for genetic engineering of heart fibroblasts.at the UW Medicine Institute for Stem Cell and Regeneration Medicine. Fibroblasts ...